US · OPK
OPKO Health, Inc.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Miami, FL 33137
- Website
- opko.com
Price · as of 2025-12-31
$1.10
Market cap 921.24M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $25.76 | +2,241.82% |
| Intrinsic Value(DCF) | $0.52 | -52.73% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $1.78 | +61.55% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $4.93 | $28.07 | $88.34 | $0.16 | $0.00 |
| 2012 | $7.48 | $35.33 | $216.52 | $0.00 | $0.00 |
| 2013 | $9.19 | $39.64 | $0.10 | $0.09 | $0.00 |
| 2014 | $14.63 | $30.21 | $0.00 | $0.00 | $0.00 |
| 2015 | $10.21 | $72.61 | $0.23 | $2.17 | $0.00 |
| 2016 | $7.95 | $42.92 | $76.42 | $2.25 | $0.00 |
| 2017 | $3.59 | $27.38 | $1.72 | $0.00 | $6.58 |
| 2018 | $2.47 | $25.59 | $3.64 | $0.58 | $0.00 |
| 2019 | $2.32 | $24.70 | $0.00 | $0.00 | $0.25 |
| 2020 | $4.44 | $33.74 | $9.80 | $1.78 | $3.09 |
| 2021 | $3.12 | $28.08 | $14.59 | $1.56 | $0.00 |
| 2022 | $1.24 | $28.54 | $0.00 | $0.00 | $15.25 |
| 2023 | $0.96 | $25.88 | $0.00 | $0.00 | $1.32 |
| 2024 | $1.90 | $25.16 | $0.20 | $0.82 | $0.65 |
| 2025 | $1.24 | $25.76 | $0.05 | $0.00 | $1.78 |
AI valuation
Our deep-learning model estimates OPKO Health, Inc.'s (OPK) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $25.76
- Current price
- $1.10
- AI upside
- +2,241.82%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.52
-52.73% upside
Graham-Dodd
—
— upside
Graham Formula
$1.78
+61.55% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| OPK | OPKO Health, Inc. | $1.10 | 921.24M | +2,242% | -53% | — | +62% | -4.21 | 0.75 | 1.56 | -20.44 | -1.44 | 3.55 | 61.01% | -36.08% | -37.20% | -17.14% | -14.89% | -10.92% | 0.33 | -2.16 | 3.97 | 3.13 | -0.89 | 29113.00% | -1490.00% | -848.00% | -20.10% | -1.22 | -13.88% | 0.00% | 0.00% | 3.09% | -4.53 | -5.20 | 1.64 | -0.35 |
| CTEV | Claritev Corporation | $13.47 | 222.6M | +1,151% | -57% | — | — | -0.83 | -1.36 | 0.25 | 10.21 | — | -0.05 | 27.61% | 4.67% | -29.45% | 632.60% | 0.76% | -5.66% | -26.64 | 0.11 | 0.86 | 0.59 | 9.71 | -8303.00% | 374.00% | 1685.00% | -5.18% | 0.45 | -0.27% | 0.00% | 0.00% | 0.00% | 107.70 | -395.26 | 5.03 | -0.45 |
| DNTH | Dianthus Therapeutics, In… | $55.19 | 2B | -29% | -75% | — | — | -9.42 | 2.27 | 128.39 | -5.19 | — | 2.27 | 100.00% | -1633.74% | -1362.77% | -32.60% | -273.59% | -30.71% | 0.00 | — | 15.22 | 14.96 | 0.21 | -6982.00% | 12063.00% | 11175.00% | -9.78% | -4.24 | -210.26% | 0.00% | 0.00% | 0.00% | -5.17 | -6.73 | 84.49 | 21.62 |
| LFMD | LifeMD, Inc. | $2.67 | 128.52M | +1,008% | +2,300% | — | — | -10.27 | -35.07 | 0.91 | -27.43 | — | -9.02 | 88.67% | -7.60% | -8.89% | 1891.64% | 123.73% | -28.61% | -4.58 | -7.40 | 0.81 | 0.72 | 1.49 | -2429.00% | 3927.00% | 677408.00% | 3.11% | 0.29 | -45.81% | 1.61% | -16.60% | 1.61% | -11.30 | 30.53 | 0.86 | -1.05 |
| NKTR | Nektar Therapeutics | $68.98 | 1.4B | -92% | -92% | — | — | -1.52 | 2.98 | 1.84 | -0.33 | — | 2.98 | 68.82% | -106.88% | -120.86% | -124.10% | 143.06% | -33.90% | 1.69 | -3.74 | 4.26 | 4.18 | -0.67 | -6017.00% | 922.00% | -842.00% | -97.90% | -2.86 | 241.42% | 0.00% | 0.00% | 15.02% | -0.27 | -0.16 | 0.29 | -16.15 |
| OCS | Oculis Holding AG | $29.41 | 1.68B | — | — | — | — | -7.08 | 8.29 | 886.66 | -7.02 | — | 10.12 | -7492.27% | -10671.14% | -12503.94% | -102.85% | 682.30% | -73.23% | 0.02 | — | 2.37 | 2.25 | 0.36 | -2862.00% | — | -1144.00% | -7.85% | -1.07 | 445.69% | 0.00% | 0.00% | 0.00% | -6.98 | -10.70 | 744.55 | 3.05 |
| PCRX | Pacira BioSciences, Inc. | $21.91 | 942.6M | +137% | -61% | -17% | -68% | 134.83 | 1.37 | 1.31 | 6.38 | — | 3.11 | 71.50% | 2.64% | 3.68% | 0.96% | 2.60% | 0.50% | 0.01 | 1.10 | 4.54 | 2.34 | -1.19 | -10744.00% | 363.00% | -2355.00% | 14.41% | 1.26 | 18.51% | 0.00% | 0.00% | 53.86% | 41.67 | 5.85 | 1.10 | 1.80 |
| PSNL | Personalis, Inc. | $9.06 | 804.57M | +263% | — | — | — | -9.95 | 3.10 | — | -8.46 | — | 3.10 | 0.00% | — | — | -35.02% | -152.75% | -26.89% | 0.12 | -429.55 | 6.76 | 6.46 | 1.30 | -3358.00% | -10000.00% | 6994.00% | -9.83% | -1.89 | -137.82% | 0.00% | 0.00% | 5.59% | -6.82 | -7.56 | — | 3.95 |
| SANA | Sana Biotechnology, Inc. | $4.21 | 1.12B | — | — | — | — | -2.23 | 2.38 | — | -2.10 | — | 11.75 | 0.00% | — | — | -99.17% | -144.07% | -50.03% | 0.38 | — | 3.54 | 3.36 | 0.13 | -2055.00% | — | -622.00% | -43.07% | -4.91 | -135.54% | 0.00% | 0.00% | 0.66% | -1.97 | -2.09 | — | -4.58 |
| TNDM | Tandem Diabetes Care, Inc… | $25.30 | 1.72B | +78% | -60% | — | — | -8.29 | 10.94 | 1.67 | -10.59 | -7.76 | 10.94 | 52.31% | -7.70% | -20.17% | -97.88% | -25.81% | -22.15% | 2.86 | -9.88 | 2.55 | 1.89 | -2.03 | 10680.00% | 793.00% | -69409.00% | -1.75% | -0.04 | -9.80% | 0.00% | 0.00% | 2.97% | -23.67 | -62.33 | 1.82 | 0.78 |
| XNCR | Xencor, Inc. | $12.77 | 911.91M | +93% | -51% | -81% | — | -9.93 | 1.44 | 7.27 | -15.55 | — | 1.46 | 91.63% | -141.35% | -73.20% | -14.00% | -41.06% | -10.06% | 0.40 | -5.56 | 6.25 | 4.84 | -4.22 | -6536.00% | 1365.00% | -3362.00% | -15.14% | -1.41 | -31.98% | 0.00% | 0.00% | 0.00% | -4.11 | -5.28 | 5.82 | 1.18 |
About OPKO Health, Inc.
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
- CEO
- Phillip Frost
- Employees
- 3K
- Beta
- 1.47
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.52 ÷ $1.10) − 1 = -52.73% (DCF, example).